Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 7/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412675 | 0.95 | PYGL (0.45) | PYGLCHEK1CYP2C9MAP4K4NPC1 | |
| SCHEMBL5427603 | 0.93 | PYGL (0.42) | PYGLCHEK1CYP2C9MAP4K4 | |
| SCHEMBL5417429 | 0.93 | CHEK1 (0.40) | PYGLCHEK1CYP2C9MAP4K4NPC1 | |
| SCHEMBL5424253 | 0.92 | PYGL (0.41) | PYGLCHEK1CYP2C9MAPT | |
| SCHEMBL5434405 | 0.91 | PYGL (0.44) | PYGLCYP2C9 | |
| SCHEMBL5417707 | 0.89 | PYGL (0.39) | PYGLCHEK1CYP2C9MAP4K4MAPT | |
| SCHEMBL5422799 | 0.88 | PYGL (0.44) | PYGLCYP2C9NPC1MAPTRAB9A | |
| SCHEMBL5420841 | 0.87 | PYGL (0.43) | PYGLCYP2C9 | |
| SCHEMBL5413025 | 0.86 | PYGL (0.43) | PYGLCYP2C9NPC1MAPTRAB9A | |
| SCHEMBL5424626 | 0.85 | MAPT (0.50) | PYGLCYP2C9MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | PYGL 2/4885CHEK1 2440/4885CYP2C9 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.